GSK Finalises $2.2 Billion Acquisition Of RAPT Therapeutics To Advance Long-Acting Anti-IgE Therapy, Expands Allergy Pipeline With Ozureprubart

GSK plc has completed its previously announced acquisition of RAPT Therapeutics, a clinical-stage biotech focused on inflammatory and immunologic diseases. The transaction strengthens GSK’s immunology pipeline and expands its presence in allergy-related therapies.

The deal includes ozureprubart, a long-acting anti-immunoglobulin E (IgE) monoclonal antibody currently in Phase IIb development for the prevention of reactions to food allergens. IgE is a validated target and remains the only approved systemic pathway shown to protect against harmful allergic and inflammatory immune responses. Approximately 94% of severe food allergies are mediated by IgE. Ozureprubart is designed to enable dosing every 12 weeks, potentially reducing the burden compared with existing anti-IgE therapies that require injections every two to four weeks. The therapy may also expand treatment access to about 25% of patients who are currently ineligible for available options.

Kaivan Khavandi, SVP, R&D Head Respiratory, Immunology & Inflammation, and Head of GSK Translational & Development Sciences, GSK said: “Ozureprubart is a promising asset that complements our expanding RI&I pipeline. Food allergies continue to place a heavy burden on patients and their families, and we are committed to progressing this potential best-in-class monoclonal antibody to deliver longer‑lasting protection.” 

Data from the ongoing Phase IIb prestIgE trial evaluating ozureprubart as a monotherapy are expected in 2027. Future Phase III studies are planned to include both adult and pediatric patients at risk of severe food allergies. The asset aligns with GSK’s established commercial infrastructure and prescriber network in allergy and immunology.

The total equity value of the acquisition is approximately $2.2 billion, with an upfront net investment of around $1.9 billion after accounting for cash acquired. GSK gains global rights to ozureprubart, excluding mainland China, Macau, Taiwan, and Hong Kong, and will assume responsibility for milestone and royalty payments owed to Shanghai Jeyou Pharmaceutical Co., Ltd. under an existing partnership agreement.